AMDL, Inc. Promotes CFO Akio Ariura to Chief Operating Officer and Expands Management Team
As COO and CFO, Mr. Ariura will lead the day-to-day operations of AMDL,including direct responsibility for AMDL's legal, financial, and businessaffairs; employee development and recruiting; and high-priority companywideinitiatives, including the implementation of its Kingdee ERP accounting systemwithin the US and China; joint venture and partnership implementations; andthe development of brand and product commercialization strategies across allbusiness divisions.
"I am extremely pleased with the Board's decision to promote Akio to ChiefOperating Officer of AMDL," said Mr. Douglas MacLellan, CEO and Chairman,AMDL. "He has been instrumental in the Company's success to date, andbroadening his role is a next step as we continue to grow and expand ourbusiness. With the support of his leadership and business expertise, AMDL ison-target to meet its gross revenue targets of $30 million to $38 million thisyear. I'm genuinely excited to have Akio in this newly created seniorexecutive position as we focus on building AMDL as a world-class andmarket-leading, diversified pharmaceutical company."
Mr. Ariura joined AMDL in 2006 as the Chief Financial Officer. He holdsmore than 20 years of experience in senior finance and business operationspositions with various public and private companies. Mr. Ariura is acertified public accountant and recognized as a Small-Cap SOX complianceexpert.
"I'm pleased to transition to this role during such a defining time inAMDL's history. With nearly 500% annual growth over the past three years we'vemanaged to thrive and evolve, despite market uncertainty and recent economicinstability," commented Mr. Ariura. "In fact, what I am most proud of is howwe've continued to expand our sales and distribution throughout China, withtop-line sales that far exceed goals set during our 2007 planning cycle."
AMDL is also expanding its senior management team with the appointment ofMr. Christopher Gee as Director of International Marketing and Sales and Mr.Raymond Gatchalian as Director of Compliance and Information Technology.
Mr. MacLellan continued, "This latest round of executive appointmentsfurther complements the top-notch team we have assembled. They are highlyqualified, dedicated professionals with the depth of experience andprofessional tenure to help take AMDL to the next level. I'm pleased towelcome Chris and Ray aboard."
Mr. Gee is a former Apple Inc. executive and tech/biotech industry veteranwith extensive IT, business operations, and international sales and marketingmanagement experience. Since 2004 he has held executive positions and workedon projects in the USA, PRC China, Hong Kong, and Taiwan including ITmanagement, product development, marketing, sales and distribution. Hisoversight spanned US and Asian business operations. His background includesthree years as a senior analyst at New York University, Stern School ofBusiness. Mr. Gee has also been a principal in various start-up companies.While at Apple Inc., Mr. Gee successfully managed business development andenterprise computing projects. Mr. Gee holds a Masters degree from KingsCollege, University of London and a Bachelors degree from New York University.
Mr. Gatchalian has an extensive background in IT audit and compliance. Hehas worked for both large and small companies including Pacificare HealthSystems, Corinthian Colleges and Fremont Investment and Loan and as aconsultant with Deloitte & Touche, Jefferson Wells, Countrywide Financial andDiagnostics Products International, with the primary responsibility ofplanning, conducting and managing system audits and providing consultingservices to various IT organizations. Mr. Gatchalian received his B.S. inComputer Information Systems from the DeVry Institute of Technology.
Headquartered in Tustin, CA with operations in Shenzhen, Jiangxi, andJilin, China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical Inc.(JPI), is a vertically integrated bio-pharmaceutical company devoted to theresearch, development, manufacturing, and marketing of diagnostic,pharmaceutical, nutritional supplement, and cosmetic products. The companyemploys approximately 320 people in the U.S. and China. The Company has anadditional 4 pharmaceutical and diagnostic products under review by variousregulatory authorities.
Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Actof 1995: The statements contained in this document include certain predictionsand projections that may be considered forward- looking statements undersecurities law. These statements involve a number of important risks anduncertainties that could cause actual results to differ materially including,but not limited to, the performance of joint venture partners, as well asother economic, competitive and technological factors involving the Company'soperations, markets, services, products, and prices. With respect to AMDL,Inc., except for the historical information contained herein, the mattersdiscussed in this document are forward-looking statements involving risks anduncertainties that could cause actual results to differ materially from thosein such forward-looking statements. Potential risks and uncertainties relatedto the Company's access to additional capital, competition and dependence onkey management.AMDL Contact: Kristine Szarkowitz Director-Investor Relations email@example.com (M) (206) 310-5323
SOURCE AMDL, Inc.
You May Also Like